CLOSE
CLOSE
Investor Relations
And information
HomeInvestor Relations› Tornier Reports Fourth Quarter and Fiscal Year 2012 Results and Provides 2013 Outlook
News Releases
View printer-friendly version << Back
Tornier Reports Fourth Quarter and Fiscal Year 2012 Results and Provides 2013 Outlook
February 21, 2013
  • OrthoHelix Acquisition Closed and Integration Proceeding Smoothly
  • Adjusted EBITDA Margin Improves for both Fourth Quarter and Full Year

AMSTERDAM--(BUSINESS WIRE)-- Tornier N.V. (NASDAQ: TRNX), a global medical device company focused on providing surgical solutions to orthopaedic extremity specialists, reported today its financial results for the fourth quarter and fiscal year ended December 30, 2012.

Revenue for the fourth quarter of 2012 reached $79.0 million compared to fourth quarter 2011 revenue of $69.0 million, an increase of 14.5% as reported and 16.0% in constant currency. Revenue for the fiscal year 2012 was $277.5 million compared to 2011 revenue of $261.2 million, an increase of 6.3% as reported and 9.4% in constant currency. Revenue for the fourth quarter and full year included $8.0 million of revenue from the acquisition of OrthoHelix Surgical Designs, Inc., which closed October 4, 2012.

Fourth quarter 2012 revenue of Tornier's extremities product categories totaled $64.7 million compared to $54.4 million a year ago, growth of 18.9% as reported and 19.8% in constant currency. Revenue of Tornier's extremities product categories for the fiscal year 2012 was $224.9 million compared to $204.9 million a year ago, growth of 9.8% as reported and 11.8% in constant currency.

Giving pro forma effect to the OrthoHelix acquisition to include OrthoHelix revenue in prior periods, Tornier's 2012 fourth quarter and full year constant currency revenue growth was 6.7% and 8.2%, respectively, and Tornier's fourth quarter and full year extremities product constant currency revenue increased 7.9% and 10.0%, respectively.

Dave Mowry, President and Chief Executive Officer of Tornier, commented, "We are pleased with our revenue performance during the fourth quarter as we closed and began the integration of our OrthoHelix acquisition, and as we faced continued challenges related to our U.S. distribution channel transition and a weak economy in Europe. Based on the benefits a strengthened U.S. distribution channel and new products such as the Ascend Flex convertible shoulder system will yield, we are excited about our prospects to return to double-digit, constant currency revenue growth on a pro forma basis during the second half of 2013."

The Company's fourth quarter 2012 adjusted EBITDA, as defined in the GAAP to non-GAAP reconciliation provided later in this release, was $11.0 million, or 13.9% of reported revenue, compared to $8.3 million, or 12.1% of revenue, in the same quarter of the prior year, an increase of 31.5%. Adjusted EBITDA for the fiscal year 2012 reached $32.9 million, or 11.9% of revenue, compared to $28.6 million, or 11.0% of revenue, in 2011, representing an increase of 15.1%.

Mr. Mowry continued, "Despite challenges, we were able to improve our adjusted EBITDA margin during the fourth quarter and fiscal year 2012. As we enter 2013, we are committed to making the investments in our distribution channel and expanded product portfolio which are necessary to return to and sustain double-digit revenue growth and adjusted EBITDA margin improvement, and to increase shareholder value."

Fourth Quarter 2012 Revenue Highlights

Extremities

  • Revenue from the upper extremity joints and trauma category was $45.8 million, an increase of 6.4% in constant currency over the same quarter in 2011. This growth was primarily led by the Company's shoulder arthroplasty portfolio, including the Aequalis™ Reversed Shoulder and Aequalis™ Ascend™. Limited launch of the Ascend Flex commenced in the fourth quarter, and this product is expected to be a major source of revenue growth in 2013.
  • Revenue from Tornier's lower extremity joints and trauma category in the fourth quarter of 2012 reached $14.8 million, an increase of 111.5% in constant currency. Fourth quarter lower extremity revenue included approximately $8 million of revenue from the acquisition of OrthoHelix. Giving pro forma effect to the OrthoHelix acquisition to include OrthoHelix revenue in the fourth quarter 2011, fourth quarter 2012 lower extremity revenue recorded constant currency growth of 15.2%. Pro forma growth was led by OrthoHelix products, particularly its new IFS Hammer Toe product line for toe deformities.
  • Revenue from the sports medicine and biologics product category was $4.2 million, an increase of 4.8% in constant currency over the same quarter in 2011, and was led by the Company's BioFiber and Conexa product lines.

Large Joints

Revenue of the Company's large joints and other product lines was $14.3 million, an increase of 1.7% over the same quarter in 2011 on a constant currency basis. In the fourth quarter, this product category decreased to 18% of reported global revenue.

Geographic Revenue

On a geographic basis as compared to the fourth quarter of 2011, Tornier's international revenue increased 3.7% as reported and 7.1% in constant currency, representing 42% of reported global revenue. Revenue in the United States increased by 23.6% and represented 58% of reported global revenue.

First Quarter 2013 Outlook

  • For the first quarter of 2013, the Company projects constant currency revenue to be in the range of $79 to $82 million, inclusive of anticipated OrthoHelix revenue of $7.5 to $8.5 million, representing constant currency growth of 6.1% to 10.1% over first quarter 2012 revenue.
  • Based on recent currency exchange rates, first quarter 2013 reported revenue is projected to be in the range of $79 to $82 million, inclusive of anticipated OrthoHelix revenue, representing reported growth of 6.1% to 10.2% over first quarter 2012 revenue.
  • First quarter 2013 extremities product categories revenue, inclusive of anticipated OrthoHelix revenue, is expected to grow 11.2% to 15.3% in constant currency.
  • The Company projects adjusted EBITDA, as described in the GAAP to non-GAAP reconciliation provided later in this release, inclusive of OrthoHelix operations, for the first quarter of 2013 to be in the range of $5.3 to $6.8 million, or 6.7% to 8.3% of reported revenue.

Fiscal Year 2013 Outlook

  • The Company projects 2013 constant currency revenue to be in the range of $310 to $322 million, inclusive of anticipated OrthoHelix revenue, representing constant currency growth of 11.7% to 16.0%.
  • Based on recent currency exchange rates, 2013 reported revenue is projected to be in the range of $312.3 to $324.3 million, inclusive of anticipated OrthoHelix revenue, representing reported growth of 12.5% to 16.9% over 2012 revenue.
  • Revenue of the Tornier extremities product categories in 2013, inclusive of anticipated OrthoHelix revenue, is expected to grow 15.6% to 20.1% in constant currency.
  • The Company projects 2013 adjusted EBITDA to be in the range of $33.0 to $38.0 million, or 10.6% to 11.7% of reported revenue. OrthoHelix is expected to have a slight positive impact on 2013 adjusted EBITDA.

Conference Call

Tornier will host a conference call today at 4:30 p.m. Eastern time to discuss its fourth quarter 2012 financial results and its initial outlook for 2013. The conference call will be available to interested parties through a live audio webcast available through the Company's website at www.tornier.com. Those without internet access may join the call from within the U.S. by dialing 1-877-673-5355; outside the U.S., dial +1-760-666-3805.

A telephone replay will be available for two weeks following the call by dialing (855) 859-2056 for domestic participants and (404) 537-3406 for international participants. When prompted, please enter the replay pin number 92470331. For those who are not available to listen to the live webcast, the call will be archived for one year on Tornier's website.

Forward-Looking Statements

Statements contained in this release that relate to future, not past, events are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on current expectations of future events and often can be identified by words such as "expect," "should," "project," "anticipate," "intend," "will," "may," "believe," "could," "would," "continue," "outlook," "guidance," "future," "prospects," other words of similar meaning or the use of future dates. Examples of forward-looking statements in this release include Tornier's financial guidance for the first quarter of 2013 and for the full year 2013, Tornier's anticipated growth prospects, expansion of adjusted EBITDA and above market double-digit growth and Tornier's expectations with respect to new products, including in particular the Ascend Flex. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause Tornier's actual results to be materially different than those expressed in or implied by Tornier's forward-looking statements. For Tornier, such uncertainties and risks include, among others, Tornier's future operating results and financial performance, fluctuations in foreign currency exchange rates, the effect of global economic conditions, the European sovereign debt crisis, and austerity measures, risks associated with Tornier's international operations and expansion, risks associated with Tornier's recent acquisition of OrthoHelix and subsequent integration activities, changes in Tornier's arrangements with its distributors and independent sales agencies and transition to direct selling models in certain geographies and territories, the timing of regulatory approvals and introduction of new products, physician acceptance, endorsement, and use of new products; the effect of regulatory actions, changes in and adoption of reimbursement rates, potential product recalls, competitor activities, Tornier's leverage and access to credit under its credit facility agreement, and the costs and effects of litigation and changes in tax and other legislation. More detailed information on these and other factors that could affect Tornier's actual results are described in Tornier's filings with the U.S. Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. Tornier undertakes no obligation to update its forward-looking statements.

About Tornier

Tornier is a global medical device company focused on serving extremities specialists who treat orthopaedic conditions of the shoulder, elbow, wrist, hand, ankle and foot. The Company's broad offering of over 100 product lines includes joint replacement, trauma, sports medicine, and biologic products to treat the extremities, as well as joint replacement products for the hip and knee in certain international markets. Since its founding approximately 70 years ago, Tornier's "Specialists Serving Specialists" philosophy has fostered a tradition of innovation, intense focus on surgeon education, and commitment to advancement of orthopaedic technology stemming from its close collaboration with orthopaedic surgeons and thought leaders throughout the world. For more information regarding Tornier, visit www.tornier.com.

Use of Non-GAAP Financial Measures

To supplement Tornier's consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP), Tornier uses certain non-GAAP financial measures in this release. Reconciliations of the non-GAAP financial measures used in this release to the most comparable U.S. GAAP measures for the respective periods can be found in tables later in this release immediately following the detail of revenue by geography. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for Tornier's financial results prepared in accordance with GAAP.

Tornier N.V.
Consolidated Statements of Operations
(in thousands, except per share data)
                   
      Three Months Ended   Twelve months ended
      (unaudited)   (unaudited)
      December 30, 2012   January 1, 2012   December 30, 2012   January 1, 2012
Revenue   $ 79,033     $ 69,042     $ 277,520     $ 261,191  
Cost of goods sold     22,435       20,174       76,964       74,882  
Cost of goods sold - acquisition related     4,539       -       4,954       -  
Gross profit     52,059       48,868       195,602       186,309  
        65.9 %     70.8 %     70.5 %     71.3 %
Operating expenses                
  Selling, general and administrative     46,290       41,553       170,447       161,448  
  Research and development     6,195       5,231       22,524       19,839  
  Amortization of intangible assets     3,708       2,834       11,721       11,282  
  Special charges     9,831       704       19,244       892  
  Total operating expenses     66,024       50,322       223,936       193,461  
                   
Operating (loss)     (13,965 )     (1,454 )     (28,334 )     (7,152 )
                   
Other income (expense)                
  Interest income     34       135       338       550  
  Interest expense     (2,303 )     (565 )     (3,733 )     (4,326 )
  Foreign currency transaction (loss)     (278 )     274       (473 )     193  
  Loss on extinguishment of debt     (593 )     -       (593 )     (29,475 )
  Other non-operating income     62       321       116       1,330  
                   
Loss before income taxes     (17,043 )     (1,289 )     (32,679 )     (38,880 )
Income tax (expense) benefit     12,240       (692 )     10,935       8,424  
                   
Consolidated net loss   $ (4,803 )   $ (1,981 )   $ (21,744 )   $ (30,456 )
                   
Net loss per share                
  Basic and diluted   $ (0.12 )   $ (0.05 )   $ (0.54 )   $ (0.80 )
                   
Weighted average ordinary shares outstanding                
  Basic and diluted     41,639       39,261       40,064       38,227  
 
Tornier N.V.
Condensed Consolidated Balance Sheets
(in thousands)
             
        December 30, 2012   January 1, 2012
        (unaudited)    
Assets          
  Current assets        
    Cash and cash equivalents   $ 31,108   $ 54,706
    Accounts receivable, net     54,192     45,908
    Inventories     86,697     79,883
    Deferred income taxes and other current assets     25,321     18,375
    Total current assets     197,318     198,872
             
  Instruments, net     51,394     49,347
  Property, plant and equipment, net     37,151     33,353
  Goodwill and intangibles, net     366,398     228,209
  Deferred income taxes and other assets     1,966     1,919
  Total assets   $ 654,227   $ 511,700
             
Liabilities and shareholders' equity        
  Current liabilities        
    Short-term borrowing and current portion of long-term debt   $ 4,595   $ 18,011
    Accounts payable     11,526     12,020
    Accrued liabilities and deferred income taxes     44,505     35,443
    Total current liabilities     60,626     65,474
             
  Other long-term debt     115,457     21,900
  Deferred income taxes and other long-term liabilities     42,065     22,866
  Total liabilities     218,148     110,240
             
  Shareholders' equity     436,079     401,460
             
  Total liabilities and shareholders' equity   $ 654,227   $ 511,700
 
Tornier N.V.
Consolidated Statements of Cash Flow
(in thousands)
                     
        Three Months Ended   Twelve Months Ended
        (unaudited)   (unaudited)
                     
        December 30, 2012   January 1, 2012   December 30, 2012   January 1, 2012
Cash flows from operating activities                
  Consolidated net loss   $ (4,803 )   $ (1,981 )   $ (21,744 )   $ (30,456 )
                     
  Adjustments to reconcile consolidated net loss to net cash provided by (used in) operating activities                
    Depreciation and amortization     8,834       7,069       30,232       28,107  
    Impairment of fixed assets     1,013       -       2,041       -  
    Lease termination costs     -       -       731       -  
    Impairment of intangible assets     4,737       210       4,737       210  
    Non-cash foreign currency (gain) loss     (278 )     (89 )     (495 )     298  
    Deferred income taxes     (4,359 )     (2,626 )     (4,506 )     (11,619 )
    Tax benefit from reversal of valuation allowance     (10,700 )     -       (10,700 )     -  
    Share-based compensation     1,722       1,806       6,830       6,547  
    Non-cash interest expense and discount amortization     524       -       524       2,040  
    Inventory obsolescence     5,258       1,182       8,171       4,996  
    Loss on extinguishment of debt     -       -       -       29,475  
    Incentive related to new facility lease     697       -       1,400       -  
    Inventory step up from acquisition     1,578       -       1,993       -  
    Other non-cash items affecting earnings     395       161       1,836       (186 )
                     
  Changes in operating assets and liabilities                
    Accounts receivable     (6,721 )     (4,139 )     (2,188 )     (4,673 )
    Inventories     832       3,076       (3,057 )     (7,939 )
    Accounts payable and accruals     3,516       6,022       87       2,573  
    Other current assets and liabilities     (209 )     431       (1,526 )     3,987  
    Other non-current assets and liabilities     1,259       1,083       65       (194 )
  Net cash provided by (used in) operating activities     3,295       12,205       14,431       23,166  
                     
Cash flows from investing activities                
  Acquisition-related cash payments     (100,366 )     (1,089 )     (104,022 )     (3,142 )
  Additions of instruments     (2,754 )     (4,692 )     (11,999 )     (19,734 )
  Purchases of property, plant, and equipment from lease incentives     (380 )     -       (1,400 )     -  
  Purchases of property, plant and equipment     (3,025 )     (2,827 )     (9,891 )     (6,599 )
  Proceeds from the sale of property, plant and equipment     1,517       -       1,517       -  
  Net cash (used in) investing activities     (105,008 )     (8,608 )     (125,795 )     (29,475 )
                     
Cash flows from financing activities                
  Change in short-term debt     (17,359 )     (2,328 )     (8,009 )     (10,513 )
  Repayments of long-term debt     (20,451 )     (1,689 )     (28,684 )     (8,147 )
  Proceeds from issuance of long-term debt     115,873       281       121,045       5,032  
  Deferred financing costs     (5,396 )     -       (5,396 )     (2,731 )
  Repayment of notes payable     -       -       -       (116,108 )
  Issuance of ordinary shares     602       362       7,710       171,577  
  Net cash provided by financing activities     73,269       (3,374 )     86,666       39,110  
                     
Effect of currency exchange rates on cash and cash equivalents     1,053       (1,365 )     1,100       (2,933 )
                     
Increase (decrease) in cash and cash equivalents     (27,391 )     (1,142 )     (23,598 )     29,868  
                     
Cash and cash equivalents at beginning of period     58,499       55,848       54,706       24,838  
                     
Cash and cash equivalents at end of period   $ 31,108     $ 54,706     $ 31,108     $ 54,706  
 
Tornier N.V.
Selected Revenue Information
(in thousands)
                             
        Three Months Ended   Twelve Months Ended
        (unaudited)       (unaudited)    
        December 30, 2012   January 1, 2012   Percent change   December 30, 2012   January 1, 2012   Percent change
Revenue by product category                        
  Upper extremity joints and trauma   $ 45,808   $ 43,424   5.5 %   $ 175,242   $ 164,064   6.8 %
  Lower extremity joints and trauma     14,776     7,011   110.8 %     34,109     26,033   31.0 %
  Sports medicine and biologics     4,163     4,010   3.8 %     15,526     14,779   5.1 %
    Total extremities     64,747     54,445   18.9 %     224,877     204,876   9.8 %
  Large joints and other     14,286     14,597   -2.1 %     52,643     56,315   -6.5 %
  Total   $ 79,033   $ 69,042   14.5 %   $ 277,520   $ 261,191   6.3 %
                             
Revenue by geography                        
  United States   $ 46,103   $ 37,299   23.6 %   $ 156,750   $ 141,496   10.8 %
  International     32,930     31,743   3.7 %     120,770     119,695   0.9 %
  Total   $ 79,033   $ 69,042   14.5 %   $ 277,520   $ 261,191   6.3 %
 
Tornier N.V.
Reconciliation of Revenue to Non-GAAP Revenue on a Constant Currency Basis
(in thousands)
                         
        Three Months Ended    
        (unaudited)    
        December 30, 2012   January 1, 2012    
        Revenue as reported   Foreign exchange impact as compared to prior period   Revenue on a constant currency basis   Revenue as reported   Percent change on a constant currency basis
Revenue by product category                    
  Upper extremity joints and trauma   $ 45,808   $ 399   $ 46,207   $ 43,424   6.4 %
  Lower extremity joints and trauma     14,776     53     14,829     7,011   111.5 %
  Sports medicine and biologics     4,163     41     4,204     4,010   4.8 %
    Total extremities     64,747     493     65,240     54,445   19.8 %
  Large joints and other     14,286     563     14,849     14,597   1.7 %
  Total   $ 79,033   $ 1,056   $ 80,089   $ 69,042   16.0 %
                         
Revenue by geography                    
  United States   $ 46,103   $ -   $ 46,103   $ 37,299   23.6 %
  International     32,930     1,056     33,986     31,743   7.1 %
  Total   $ 79,033   $ 1,056   $ 80,089   $ 69,042   16.0 %
                         
                         
        Twelve Months Ended    
        (unaudited)    
        December 30, 2012   January 1, 2012    
        Revenue as reported   Foreign exchange impact as compared to prior period   Revenue on a constant currency basis   Revenue as reported   Percent change on a constant currency basis
Revenue by product category                    
  Upper extremity joints and trauma   $ 175,242   $ 3,425   $ 178,667   $ 164,064   8.9 %
  Lower extremity joints and trauma     34,109     403     34,512     26,033   32.6 %
  Sports medicine and biologics     15,526     317     15,843     14,779   7.2 %
    Total extremities     224,877     4,145     229,022     204,876   11.8 %
  Large joints and other     52,643     3,985     56,628     56,315   0.6 %
  Total   $ 277,520   $ 8,130   $ 285,650   $ 261,191   9.4 %
                         
Revenue by geography                    
  United States   $ 156,750   $ -   $ 156,750   $ 141,496   10.8 %
  International     120,770     8,130     128,900     119,695   7.7 %
  Total   $ 277,520   $ 8,130   $ 285,650   $ 261,191   9.4 %
 
Tornier N.V.
Reconciliation of Revenue to Non-GAAP Pro forma Revenue
(in thousands)
                                         
       

Three Months Ended

   
        (unaudited)    
        December 30, 2012   January 1, 2012    
        Revenue as reported   Foreign exchange impact as compared to prior period   Revenue on a constant currency basis   * Proforma adjustment for acquisitions   Proforma Revenue on a constant currency basis   Revenue as reported   * Proforma adjustment for acquisitions   Proforma Revenue on a constant currency basis   Percent change on a constant currency basis
Revenue by product category                                    
  Upper extremity joints and trauma   $ 45,808   $ 399   $ 46,207   $ 11   $ 46,218   $ 43,424   $ 170   $ 43,594   6.0 %
  Lower extremity joints and trauma     14,776     53     14,829     282     15,111     7,011     6,103     13,114   15.2 %
  Sports medicine and biologics     4,163     41     4,204     -     4,204     4,010     -     4,010   4.8 %
    Total extremities     64,747     493     65,240     293     65,533     54,445     6,273     60,718   7.9 %
  Large joints and other     14,286     563     14,849     -     14,849     14,597     -     14,597   1.7 %
  Total   $ 79,033   $ 1,056   $ 80,089   $ 293   $ 80,382   $ 69,042   $ 6,273   $ 75,315   6.7 %
                                         
                                         
                                         
        Twelve Months Ended    
        (unaudited)    
        December 30, 2012   January 1, 2012    
        Revenue as reported   Foreign exchange impact as compared to prior period   Revenue on a constant currency basis   * Proforma adjustment for acquisitions   Proforma Revenue on a constant currency basis   Revenue as reported   * Proforma adjustment for acquisitions   Proforma Revenue on a constant currency basis   Percent change on a constant currency basis
Revenue by product category                                    
  Upper extremity joints and trauma   $ 175,242   $ 3,425   $ 178,667   $ 807   $ 179,474   $ 164,064   $ 830   $ 164,894   8.8 %
  Lower extremity joints and trauma     34,109     403     34,512     20,017     54,529     26,033     21,349     47,382   15.1 %
  Sports medicine and biologics     15,526     317     15,843         15,843     14,779         14,779   7.2 %
    Total extremities     224,877     4,145     229,022     20,824     249,846     204,876     22,179     227,055   10.0 %
  Large joints and other     52,643     3,985     56,628     -     56,628     56,315     -     56,315   0.6 %
  Total   $ 277,520   $ 8,130   $ 285,650   $ 20,824   $ 306,474   $ 261,191   $ 22,179   $ 283,370   8.2 %
                                         

Notes:

                                   

* - Represents Pro forma Revenue adjustment for closing date of OrthoHelix acquisition related to the respective period.

 
Tornier N.V.
Reconciliation of Net Loss to
Non-GAAP Adjusted Earnings Before Interest, Taxes, Depreciation
and Amortization (EBITDA)
(in thousands)
                     
        Three Months Ended   Twelve Months Ended
        (unaudited)   (unaudited)
        December 30, 2012   January 1, 2012   December 30, 2012   January 1, 2012
Revenue, as reported   $ 79,033     $ 69,042     $ 277,520     $ 261,191  
                     
Net loss, as reported   $ (4,803 )   $ (1,981 )   $ (21,744 )   $ (30,456 )
                     
  Interest income     (34 )     (135 )     (338 )     (550 )
  Interest expense     2,303       565       3,733       4,326  
  Income tax expense (benefit)     (12,240 )     692       (10,935 )     (8,424 )
  Depreciation     5,126       4,445       18,511       17,035  
  Amortization     3,708       2,834       11,721       11,282  
                     
  Subtotal Non-GAAP EBITDA (Loss)     (5,940 )     6,420       948       (6,787 )
                     
  Other non-operating (income) expense     (62 )     (321 )     (116 )     (1,330 )
  Foreign currency transaction (gain) loss     278       (274 )     473       (193 )
  Share-based compensation     1,722       1,806       6,830       6,547  
  Loss on extinguishment of debt     593       -       593       29,475  
  Inventory step-up from acquisition     1,578       -       1,993       -  
  Inventory product rationalization due to acquisition     2,961       -       2,961       -  
  Special Charges                
    Facilities consolidation     1,111       -       6,357       -  
    Acquisition and integration costs     2,568       -       3,546       -  
    Impairment of intangibles     4,737       -       4,737       -  
    Distribution channel transition costs     554       -       1,374       -  
    Management exit costs     861       632       1,235       632  
    Italy bad debt expense     -       -       1,995       -  
    Other     -       72       -       260  
                     
Non-GAAP Adjusted EBITDA   $ 10,961     $ 8,335     $ 32,926     $ 28,604  
                     
Non-GAAP Adjusted EBITDA Margin     13.9 %     12.1 %     11.9 %     11.0 %
 
Tornier N.V.
Reconciliation of Net Income (Loss) and Earnings per Share
to Adjusted Net Income (Loss) and Adjusted Earnings per Share
(in thousands)
                     
        Three Months Ended   Twelve Months Ended
        (unaudited)   (unaudited)
        December 30, 2012   January 1, 2012   December 30, 2012   January 1, 2012
Net loss, as reported   $ (4,803 )   $ (1,981 )   $ (21,744 )   $ (30,456 )
                     
  Loss on extinguishment of debt, net of tax     479       -       479       21,990  
  Gain on resolution of contingent liability     -       -       -       (1,000 )
  Inventory step-up from acquisition, net of tax     1,534       -       1,869       -  
  Inventory product rationalization due to acquisition, net of tax     2,916       -       2,916       -  
  Tax benefit from reversal of valuation allowance     (10,700 )     -       (10,700 )     -  
  Special Charges, net of tax                
    Facilities consolidation     1,119       -       6,097       -  
    Acquisition and integration costs     2,564       -       3,534       -  
    Impairment of intangibles     4,737           4,737      
    Distribution channel transition costs     554       -       1,374       -  
    Management exit costs     861       632       1,235       632  
    Italy bad debt expense     -       -       1,995       -  
    Other     -       72       -       260  
                     
Non-GAAP Adjusted Net loss     (739 )     (1,277 )     (8,208 )     (8,574 )
                     
Net loss per share, as reported                
  Basic and diluted   $ (0.12 )   $ (0.05 )   $ (0.54 )   $ (0.80 )
                     
  Loss on extinguishment of debt, net of tax     0.01       -       0.01       0.58  
  Gain on resolution of contingent liability     -       -       -       (0.03 )
  Inventory step-up from acquisition, net of tax     0.04       -       0.05       -  
  Inventory product rationalization due to acquisition, net of tax     0.07       -       0.07       -  
  Tax benefit from reversal of valuation allowance     (0.26 )     -       (0.27 )     -  
  Special Charges, net of tax     -       -       -       -  
    Facilities consolidation     0.03       -       0.15       -  
    Acquisition and integration costs     0.06       -       0.09       -  
    Impairment of intangibles     0.11       -       0.12       -  
    Distribution channel transition costs     0.02       -       0.04       -  
    Management exit costs     0.02       0.02       0.03       0.02  
    Italy bad debt expense     -       -       0.05       -  
    Other     -       -       -       0.01  
                     
Non-GAAP Adjusted Net loss per share                
  Basic and diluted   $ (0.02 )   $ (0.03 )   $ (0.20 )   $ (0.22 )
                     
Weighted average ordinary shares outstanding                
  Basic and diluted     41,639       39,261       40,064       38,227  
 
Tornier N.V.
Reconciliation of Net Cash Provided by (Used in) Operating Activities
to Non-GAAP Free Cash Flow
(in thousands)
                     
        Three Months Ended   Twelve Months Ended
        (unaudited)   (unaudited)
                     
        December 30, 2012   January 1, 2012   December 30, 2012   January 1, 2012
                     
Net cash provided by (used in) operating activities, as reported   $ 3,295     $ 12,205     $ 14,431     $ 23,166  
                     
  Adjusted for:                
    Cash paid related to Facilities Consolidation     2,216       -       4,811       -  
    Additions of instruments, as reported     (2,754 )     (4,692 )     (11,999 )     (19,734 )
    Purchases of property, plant and equipment, as reported     (3,405 )     (2,827 )     (11,291 )     (6,599 )
    Purchases of property, plant and equipment related to Facilities Consolidation     636       -       2,997       -  
                     
Non-GAAP Adjusted free cash flow   $ (12 )   $ 4,686     $ (1,051 )   $ (3,167 )
 
Tornier N.V.
Reconciliation of Gross Margins and Gross Margin %
to Non-GAAP Adjusted Gross Margins and Gross Margin %
(in thousands)
                   
      Three Months Ended   Twelve Months Ended
      (unaudited)   (unaudited)
                   
      December 30, 2012   January 1, 2012   December 30, 2012   January 1, 2012
                   
Revenue, as reported   $ 79,033     $ 69,042     $ 277,520     $ 261,191  
                   
Gross Margins, as reported   $ 52,059     $ 48,868     $ 195,602     $ 186,309  
Gross Margin %, as reported     65.9 %     70.8 %     70.5 %     71.3 %
                   
  Adjusted for:                
  Inventory step-up due to acquisition     1,578       -       1,993       -  
  Product rationalization due to acquisition     2,961       -       2,961       -  
                   
Non-GAAP Adjusted Gross Margins     56,598       48,868       200,556       186,309  
Non-GAAP Adjusted Gross Margin %     71.6 %     70.8 %     72.3 %     71.3 %
 
Tornier N.V.
Reconciliation of Projected 2013 Operating Income
to Projected Non-GAAP Adjusted EBITDA
(in thousands)
                     
        Three Months Ended   Twelve Months Ended
        (unaudited)   (unaudited)
        March 31, 2013   December 29, 2013
       

Low

 

High

 

Low

 

High

                     
Revenue   $ 79,000     $ 82,000     $ 312,300     $ 324,300  
Operating Income (Loss)   $ (10,900 )   $ (6,900 )   $ (32,000 )   $ (20,000 )
                     
 

Adjusted for:

               
    Inventory step-up due to acquisition     1,800       1,600       6,000       5,500  
    Depreciation and Amortization Expense     9,200       8,700       37,500       35,000  
    Share-based compensation     2,200       1,900       9,500       7,500  
    Special charges     3,000       1,500       12,000       10,000  
 

Total Adjustments

    16,200       13,700       65,000       58,000  
                     
Non-GAAP Adjusted EBITDA   $ 5,300     $ 6,800     $ 33,000     $ 38,000  
Non-GAAP Adjusted EBITDA Margin     6.7 %     8.3 %     10.6 %     11.7 %
                     
Note:                

Special charges includes anticipated charges relating to the integration of OrthoHelix, U.S. sales channel efforts to create a dedicated upper extremities and a lower extremities channel, and conversion to a direct sales channel in certain U.S. and international territories.

Tornier believes the non-GAAP financial measures presented above provide additional meaningful information for measuring Tornier's financial performance and are measures frequently used by Tornier's management, as well as securities analysts and investors. Tornier uses the non-GAAP financial measures as supplemental measures of its performance and believes such measures facilitate operating performance comparisons from period to period and company to company by factoring out potential differences caused by charges not related to Tornier's regular, ongoing business, including non-cash charges, certain large and unpredictable charges, acquisitions, dispositions and tax positions. Tornier's management uses the non-GAAP financial measures to assess the performance of Tornier's core operations, analyze underlying trends in Tornier's businesses, establish operational goals and forecasts, and evaluate Tornier's performance period over period and in relation to the operating results of its competitors. Tornier's management uses the non-GAAP financial measures to help allocate its resources to both ongoing and prospective business initiatives and to help make budgeting and spending decisions, for example, between product development expenses, research and development expenses, and selling, general and administrative expenses. Tornier's management is evaluated on the basis of several of these non-GAAP financial measures when determining achievement of performance incentive compensation goals.

Tornier believes that non-GAAP financial measures have limitations as analytical tools since they do not reflect all of the amounts associated with Tornier's operating results as determined in accordance with GAAP and should only be used to evaluate Tornier's operating results in conjunction with the corresponding GAAP measures. Accordingly, revenue on a constant currency basis should not be used as a substitute for revenue, EBITDA, adjusted EBITDA, adjusted net income (loss) and adjusted net income (loss) per share should not be used as a substitute for net income or net income per share; adjusted EBITDA margin should not be used as a substitute for net margin or operating margin; free cash flow should not be used as a substitute for cash flows from operations; and adjusted gross margin and gross margin percentage should not be used as a substitute for gross margin or gross margin as a percentage of revenue, in each case as determined in accordance with GAAP. Neither EBITDA, adjusted EBITDA, adjusted EBITDA margin, adjusted net income (loss), adjusted net income (loss) per share, free cash flow, adjusted gross margin and gross margin as a percentage of revenue, should be an indication of whether cash flow will be sufficient to fund Tornier's cash requirements. Additionally, the calculation of non-GAAP financial measures is not based on any comprehensive or standard set of accounting rules or principles. Accordingly, Tornier's definitions of revenue on a constant currency basis, EBITDA, adjusted EBITDA, adjusted EBITDA margin, adjusted net income (loss), adjusted net income (loss) per share, free cash flow, adjusted gross margin and gross margin as a percentage of revenue, may differ from the definitions of other companies using the same or similar names limiting, to some extent, the usefulness of such measures for comparison purposes.

For further information regarding why Tornier believes that these non-GAAP financial measures provide useful information to investors, the specific manner in which management uses these measures, and some of the limitations associated with the use of these measures, please refer to Tornier's current report on Form 8-K filed today with the Securities and Exchange Commission which attaches this release as an exhibit. This current report on Form 8-K is available on the SEC's website at www.sec.gov. or on Tornier's website at www.tornier.com.

Tornier N.V.
Shawn McCormick
Chief Financial Officer
952-426-7646
shawn.mccormick@tornier.com

Source: Tornier N.V.

 

 

News Provided by Acquire Media